SCHEMBL3767170

SCHEMBL3767170

Cc1cccc(-c2csc(Br)n2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 2/20 0.57
ATP4B P51164 2/20 0.57
MAPT P10636 3/20 0.51
RAB9A P51151 3/20 0.51
ALDH1A1 P00352 2/20 0.51
HPGD P15428 1/20 0.51
HK1 P19367 1/20 0.51
HKDC1 Q2TB90 1/20 0.51
TSHR P16473 1/20 0.50
RECQL P46063 1/20 0.50
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
LTA4H P09960 1/20 0.46
C1S P09871 1/20 0.45
IDO1 P14902 1/20 0.45
METAP2 P50579 1/20 0.45
PDE3B Q13370 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30087395 1.00 ATP4A (0.57) ATP4AATP4BMAPTRAB9AALDH1A1
SCHEMBL8257849 0.84 RECQL (0.70) ATP4AATP4BMAPTRAB9AALDH1A1
SCHEMBL7120830 0.82 ALDH1A1 (0.65) ATP4AATP4BMAPTRAB9AALDH1A1
SCHEMBL4076416 0.81 ALDH1A1 (0.74) MAPTRAB9AALDH1A1HPGDHK1
SCHEMBL9454811 0.81 ATP4A (0.56) ATP4AATP4BMAPTRAB9AALDH1A1
SCHEMBL19196250 0.80 ALDH1A1 (0.53) MAPTRAB9AALDH1A1HPGDHK1
SCHEMBL12868318 0.79 ATP4A (0.55) ATP4AATP4BMAPTRAB9AALDH1A1
SCHEMBL19051397 0.79 SREBF2 (0.71) ATP4AATP4BMAPTRAB9AALDH1A1
SCHEMBL3764574 0.79 KDM4E (0.70) MAPTRAB9AALDH1A1HPGDHK1
SCHEMBL25735690 0.79 TSHR (0.68) MAPTRAB9AALDH1A1HPGDHK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260130921-A1 TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS AcuraStem Incorporated (US) 2026-05-14 US disclosed
US-20240352026-A1 PIKFYVE KINASE INHIBITORS AcuraStem Incorporated 2024-10-24 US disclosed
US-20240197747-A1 TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS AcuraStem, Inc. (US) 2024-06-20 US disclosed
US-20230135152-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 US disclosed
US-20230135152-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 US disclosed
US-20230135152-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-05-04 US disclosed
EP-4103281-A1 PIKFYVE KINASE INHIBITORS Acurastem Inc. (US) 2022-12-21 EP disclosed
CN-113912595-A Compound containing thiazole or thiadiazole structure and application thereof 中国药科大学 2022-01-11 CN disclosed
US-20210338683-A1 TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-11-04 US disclosed
WO-2021163727-A1 PIKFYVE KINASE INHIBITORS AcuraStem Incorporated (US) 2021-08-19 WO disclosed
WO-2021163727-A1 PIKFYVE KINASE INHIBITORS AcuraStem Incorporated (US) 2021-08-19 WO disclosed
EP-3676264-A1 PIKFYVE KINASE INHIBITORS Acurastem Inc. (US) 2020-07-08 EP disclosed
US-20200199136-A1 PIKFYVE KINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-06-25 US disclosed
WO-2019046316-A1 PIKFYVE KINASE INHIBITORS ACURASTEM INC. (US) 2019-03-07 WO disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-7851473-B2 Amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-14 US disclosed
US-20080312226-A1 Amide Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 US disclosed
EP-1813606-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135152-A1 PIKFYVE KINASE INHIBITORS PIKFYVE, PIP5K1B, PIP5K1C ATP4A 2357/4885ATP4B 2648/4885MAPT 1501/4885
US-20200199136-A1 PIKFYVE KINASE INHIBITORS PIKFYVE, PIP5K1B, PIK3CA ATP4A 2021/4885ATP4B 2529/4885MAPT 1959/4885
US-20080312226-A1 Amide Compound FAAH, FAAH2, CNR2 ATP4A 1719/4885ATP4B 2624/4885MAPT 3805/4885
US-20240352026-A1 PIKFYVE KINASE INHIBITORS PIKFYVE, PIP5K1B, PIK3CA ATP4A 2021/4885ATP4B 2529/4885MAPT 1959/4885
US-20240197747-A1 TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS PIKFYVE, TMPRSS2, TMPRSS4 ATP4A 3163/4885ATP4B 2406/4885MAPT 2796/4885
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A ATP4A 2758/4885ATP4B 2711/4885MAPT 4667/4885
US-20260130921-A1 TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS TMPRSS2, TMPRSS11D, TMPRSS6 ATP4A 1543/4885ATP4B 1101/4885MAPT 2715/4885
US-20210338683-A1 TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS PIKFYVE, TMPRSS2, TMPRSS4 ATP4A 3163/4885ATP4B 2406/4885MAPT 2796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.